157 related articles for article (PubMed ID: 7602366)
1. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
[TBL] [Abstract][Full Text] [Related]
2. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
Ann Oncol; 1993 Sep; 4(8):673-8. PubMed ID: 8240998
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
[TBL] [Abstract][Full Text] [Related]
16. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
[TBL] [Abstract][Full Text] [Related]
17. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
van Warmerdam LJ; Creemers GJ; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens JH; ten Bokkel Huinink WW; Davies BE; Maes RA; Verweij J; Beijnen JH
Cancer Chemother Pharmacol; 1996; 38(3):254-60. PubMed ID: 8646800
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]